Literature DB >> 27206936

Provider understanding of the 2013 ACC/AHA cholesterol guideline.

Salim S Virani1, Yashashwi Pokharel2, Lynne Steinberg3, Winston Chan4, Julia M Akeroyd4, Saqib Ali Gowani5, Ankur Kalra6, Venkateshwar Polsani7, Michael D Miedema6, Peter H Jones2, Vijay Nambi8, Laura A Petersen4, Christie M Ballantyne2.   

Abstract

BACKGROUND: Providers' understanding of the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline in clinical practice is not known.
METHODS: We designed a questionnaire, which was administered to internal medicine, family practice, cardiology, and endocrinology providers at 21 venues across the United States. We compared responses between providers in training or practice and between specialists (cardiology and endocrinology) and nonspecialists (internal medicine and family practice).
RESULTS: Response rate was 72.1% (543 of 725). About 43% of the providers in training and 48% of those in practice indicated having read the guideline. Almost 50% in each group were unable to identify the 4 statin benefit groups and a large proportion (41% in training and 49% in practice) were not aware of the ≥7.5% 10-year risk threshold for discussion regarding statin therapy. Most (∼85%) were unaware of the 4 outcomes assessed by the 10-year ASCVD risk equation. About 36% of the providers in training and 48% in practice could identify a patient with familial hypercholesterolemia and start a discussion regarding statin therapy. Only 27.6% of the providers in training and 40.4% in practice recommended repeating a lipid panel 6-8 weeks after starting statins in a patient with recent myocardial infarction. Similar gaps were noted when comparing specialists to nonspecialists.
CONCLUSION: Most providers do not completely understand the 2013 ACC/AHA cholesterol guideline. As an unintended consequence, providers are moving away from lipid testing to document response and adherence to statin therapy. Efforts are needed to address these gaps. Published by Elsevier Inc.

Entities:  

Keywords:  ASCVD risk; Cholesterol guideline; Familial hypercholesterolemia; Practice; Survey

Mesh:

Substances:

Year:  2015        PMID: 27206936     DOI: 10.1016/j.jacl.2015.11.002

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  29 in total

1.  The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.

Authors:  Salim S Virani
Journal:  Tex Heart Inst J       Date:  2016-08-01

2.  Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.

Authors:  Yashashwi Pokharel; Fengming Tang; Philip G Jones; Vijay Nambi; Vera A Bittner; Ravi S Hira; Khurram Nasir; Paul S Chan; Thomas M Maddox; William J Oetgen; Paul A Heidenreich; William B Borden; John A Spertus; Laura A Petersen; Christie M Ballantyne; Salim S Virani
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

3.  Physicians Voluntarily Using an EHR-Based CDS Tool Improved Patients' Guideline-Related Statin Prescription Rates: A Retrospective Cohort Study.

Authors:  Timothy S Chang; Ashwin Buchipudi; Gregg C Fonarow; Michael A Pfeffer; Jennifer S Singer; Eric M Cheng
Journal:  Appl Clin Inform       Date:  2019-06-19       Impact factor: 2.342

Review 4.  Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2016-12-12

5.  Effects of the 2013 American College of Cardiology/American Heart Association guidelines on racial and ethnic disparities in statin treatment among diabetics.

Authors:  Gregory A Phelps; Yanru Qiao; Merrion G Buckley; Junling Wang; Minghui Sam Li; Soumitra S Bhuyan; Marie A Chisholm-Burns
Journal:  Res Social Adm Pharm       Date:  2019-07-25

6.  Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease.

Authors:  Yevgeniy Khariton; Krishna K Patel; Paul S Chan; Yashashwi Pokharel; Jingyan Wang; John A Spertus; David M Safley; William R Hiatt; Kim G Smolderen
Journal:  Clin Cardiol       Date:  2018-10-19       Impact factor: 2.882

7.  Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines.

Authors:  H Robert Superko; Paul T Williams; Michael Dansinger; Ernst Schaefer
Journal:  Clin Cardiol       Date:  2018-11-30       Impact factor: 2.882

Review 8.  Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Authors:  Matthew R Deshotels; Salim S Virani; Christie M Ballantyne
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

Review 9.  Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry).

Authors:  Angela Lowenstern; Ann Marie Navar; Shuang Li; Salim S Virani; Anne C Goldberg; Michael J Louie; L Veronica Lee; Eric D Peterson; Tracy Y Wang
Journal:  Am J Cardiol       Date:  2019-01-04       Impact factor: 2.778

10.  Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.

Authors:  Salim S Virani; Kevin F Kennedy; Julia M Akeroyd; Pamela B Morris; Vera A Bittner; Frederick A Masoudi; Neil J Stone; Laura A Petersen; Christie M Ballantyne
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.